Clinical trial
Chloroquine as an Anti-Autophagy Drug in Stage IV Small Cell Lung Cancer (SCLC)…
NCT00969306 · Maastricht Radiation Oncology, Other · Terminated
Key facts
| NCT number | NCT00969306 |
|---|---|
| Title | Chloroquine as an Anti-Autophagy Drug in Stage IV Small Cell Lung Cancer (SCLC) Patients |
| Official title | Chloroquine as an Anti-autophagy Drug in Stage IV Small Cell Lung Cancer (SCLC) Patients: A Phase 1 Trial |
| Acronym | Chloroquine IV |
| Lead sponsor | Maastricht Radiation Oncology, Other |
| Collaborators | Maastricht University Medical Center National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Chloroquine, A-CQ 100 |
| Enrollment | 5 |
| Start date | Sep 1, 2013 |
| Primary completion | Jun 1, 2016 |
| Completion | Jun 1, 2016 |
| First posted | Sep 1, 2009 |
| Last update posted | Feb 15, 2019 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: